‘In this cohort of patients hospitalised for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomised, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)’
In this short conclusion in its introduction, the paper published by the New England Journal of Medicine, mentions specifically who funded it.
Read here (New England Journal of Medicine, April 10, 2020)
Worst ever Covid variant? Omicron
John Campbell shares his findings on Omicron. View here (Youtube, Nov 27, 2021)
-
‘Infectious diseases experts have questioned the need for continued widespread enforcement of TraceTogether and SafeEntry rules as Singapore...
-
‘Much was riding on the Oxford vaccine, a British-led endeavour also involving UK drugs firm AstraZeneca. Prime Minister Boris Johnson’s gov...
-
‘It appears that vaccine hesitancy is due to lack of information and trust. Despite the government's assurances about Covid-19 vaccines,...